Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the cla
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
Why Nektar Therapeutics Stock Rocked it Today
07:13pm, Monday, 20'th Apr 2026
The successful phase 2b trial followed a previous study that was affected by apparent enrollment errors. The company plans to advance the drug through its pipeline.
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
04:17pm, Monday, 20'th Apr 2026
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
Nektar Therapeutics Announces Proposed Public Offering
04:01pm, Monday, 20'th Apr 2026
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunothera
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Nektar Therapeutics (NASDAQ: NKTR) during the period from February 26, 2025 through December 15, 2025 may wish
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness.
11:43am, Monday, 20'th Apr 2026
Nektar Therapeutics releases positive results from its trial for the treatment of alopecia areata.
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday
10:34am, Monday, 20'th Apr 2026
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
10:17am, Monday, 20'th Apr 2026
LOS ANGELES, April 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
Why Are Nektar Shares Up Monday?
09:16am, Monday, 20'th Apr 2026
The company said the REZOLVE-AA extension results demonstrated continued improvement in patients with severe-to-very-severe alopecia areata treated with rezpegaldesleukin, with responses strengthening
29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatment Increasing proportions
